March 11, 2024 04:08 PM EDTUpdated 05:20 PM
Pharma

CBO hints that Medicare may soon cov­er obe­si­ty drugs for their car­dio­vas­cu­lar ben­e­fits

Zachary Brennan

Senior Editor

Medicare is star­ing down tens of bil­lions of dol­lars in fu­ture ex­pens­es if it be­gins cov­er­ing obe­si­ty drugs like No­vo Nordisk’s We­govy and Eli Lil­ly’ …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times